Abstract
Atherosclerosis is a complex inflammatory process characterized by the cross-talk between excessive inflammation and lipid accumulation. In the past few years, compelling evidence suggests that statins can decrease vascular inflammation and attenuate the development of atherosclerosis through their so-called “pleiotropic effects”. These cholesterol-independent effects are predominantly due to their ability to inhibit isoprenoid synthesis. In particular, inhibition of geranylgeranylpyrophosphate synthesis leads to inhibition of Rho and its downstream target, Rho-kinase (ROCK). Thus, one of the beneficial effects of statin therapy could be due to inhibitory effects on ROCK. ROCK is involved in mediating diverse cellular functions such as smooth muscle contraction, cell migration and proliferation. While increased ROCK activity is associated with endothelial dysfunction, cerebral ischemia, coronary vasospasms and metabolic syndrome, the inhibition of ROCK by statins or selective ROCK inhibitors leads to up-regulation of endothelial nitric oxide synthase (eNOS), decreased vascular inflammation, and reduced atherosclerotic plaque formation. This review will focus on the impact of ROCK in cardiovascular disease and its contributory role to vascular inflammation and the atherosclerosis.
Keywords: Rho-kinase, inflammation, atherosclerosis, statin
Current Pharmaceutical Design
Title: Rho Kinase: An Important Mediator of Atherosclerosis and Vascular Disease
Volume: 15 Issue: 27
Author(s): Qian Zhou and James K. Liao
Affiliation:
Keywords: Rho-kinase, inflammation, atherosclerosis, statin
Abstract: Atherosclerosis is a complex inflammatory process characterized by the cross-talk between excessive inflammation and lipid accumulation. In the past few years, compelling evidence suggests that statins can decrease vascular inflammation and attenuate the development of atherosclerosis through their so-called “pleiotropic effects”. These cholesterol-independent effects are predominantly due to their ability to inhibit isoprenoid synthesis. In particular, inhibition of geranylgeranylpyrophosphate synthesis leads to inhibition of Rho and its downstream target, Rho-kinase (ROCK). Thus, one of the beneficial effects of statin therapy could be due to inhibitory effects on ROCK. ROCK is involved in mediating diverse cellular functions such as smooth muscle contraction, cell migration and proliferation. While increased ROCK activity is associated with endothelial dysfunction, cerebral ischemia, coronary vasospasms and metabolic syndrome, the inhibition of ROCK by statins or selective ROCK inhibitors leads to up-regulation of endothelial nitric oxide synthase (eNOS), decreased vascular inflammation, and reduced atherosclerotic plaque formation. This review will focus on the impact of ROCK in cardiovascular disease and its contributory role to vascular inflammation and the atherosclerosis.
Export Options
About this article
Cite this article as:
Zhou Qian and Liao K. James, Rho Kinase: An Important Mediator of Atherosclerosis and Vascular Disease, Current Pharmaceutical Design 2009; 15 (27) . https://dx.doi.org/10.2174/138161209789057986
DOI https://dx.doi.org/10.2174/138161209789057986 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vildagliptin Restores Renal Myogenic Function and Attenuates Renal Sclerosis Independently of Effects on Blood Glucose or Proteinuria in Zucker Diabetic Fatty Rat
Current Vascular Pharmacology Towards a Better Understanding of Cardiac and Vascular Disease in Patients with Chronic Kidney Disease
Current Cardiology Reviews Neuroprotective Effects of Agomelatine and Vinpocetine Against Chronic Cerebral Hypoperfusion Induced Vascular Dementia
Current Neurovascular Research Class II Phosphoinositide 3-Kinases as Potential Novel Drug Targets
Current Signal Transduction Therapy Vitamin E-Related Inhibition of Monocyte 5-Lipoxygenase and Cardiovascular Outcome in Maintenance Hemodialysis Patients
Recent Patents on Inflammation & Allergy Drug Discovery Gene-Nutrient Interaction in Type 2 Diabetes: An Appraisal of the Role of the Peroxisome Proliferator-Activated Receptor Pathway
Current Pharmacogenomics Strategies to Reduce Vascular Risk Associated with Obesity
Current Vascular Pharmacology Medicinal Properties of Mangiferin, Structural Features, Derivative Synthesis, Pharmacokinetics and Biological Activities
Mini-Reviews in Medicinal Chemistry Transforming Growth Factor β Signaling Perturbation in the Loeys-Dietz Syndrome
Current Medicinal Chemistry Mitochondrial Mutations in Atherosclerosis: New Solutions in Research and Possible Clinical Applications
Current Pharmaceutical Design Cyclooxygenase Inhibition and Atherothrombosis
Current Drug Targets The Nitric Oxide Signaling Pathway in the Penis
Current Pharmaceutical Design Meet Our Editorial Board Member
Cardiovascular & Hematological Disorders-Drug Targets Mesenchymal Stem Cells: A Good Candidate for Restenosis Therapy?
Current Vascular Pharmacology PET Imaging and Coronary Circulatory Function: Non-Invasive Mechanistic Insights and Cardiovascular Prognosis
Current Cardiology Reviews Primary Prevention of Ischaemic Stroke in Atrial Fibrillation: New Oral Anticoagulant Drugs for all?
Current Vascular Pharmacology Cellular Senescence in Cardiovascular Diseases: Potential Age-Related Mechanisms and Implications for Treatment
Current Pharmaceutical Design Endovascular Repair of Thoracic Aortic Aneurysms
Recent Patents on Cardiovascular Drug Discovery Caveolae and Caveolin-1: Novel Potential Targets for the Treatment of Cardiovascular Disease
Current Pharmaceutical Design Irbesartan and Hydrochlorothiazide Association in the Treatment of Hypertension
Current Vascular Pharmacology